

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Variant rs9644568 in the intergenic region downstream of the LPL gene is associated with high LDL cholesterol levels among Filipinos

Eva Maria C. Cutiongco–de la Paz^{1,2*}¶, Jose B. Nevado, Jr.¹¶, Lourdes Ella G. Santos³¶, Aimee Yvonne Criselle L. Aman^{1,2}¶, Jose Donato A. Magno³¶, Paul Ferdinand M. Reganit³¶, Richard Henry P. Tiongco II³¶, Deborah Ignacia D. Ona³¶, Felix Eduardo R. Punzalan³¶, Elmer Jasper B. Llanes³¶, Jaime Alfonso M. Aherrera³¶, Carla Mae O. Fernandez¹¶, Lauro L. Abrahan IV³¶, Charlene F. Agustin³¶, Adrian John P. Bejarin^{1,2}¶, and Rody G. Sy³¶

¹Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Philippines

²Philippine Genome Center, University of the Philippines Diliman, Quezon City, Philippines

³Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Philippines

*corresponding author

E-mail: eccutiongcodelapaz@up.edu.ph

¶These authors contributed equally to this work

Abstract

25
26
27 High blood level of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for
28 cardiovascular disease. Although genetic variants linked to high LDL-C have been studied in other
29 populations, there have been no previous studies among Filipinos. This study aims to determine
30 the association of candidate genetic variants to high LDL-C. We performed an age- and sex-
31 matched case-control study that compared Filipino participants with high LDL-C levels (n=60)
32 with controls (n=60). DNA was extracted from blood samples and genotyped for candidate SNPs
33 using a customized microarray chip. Logistic regression analyses were used to determine the
34 composite association of genetic and clinical variables to the condition. Of the initial eleven SNPs
35 associated with high LDL-C in univariate analyses, only the variant rs9644568 in the intergenic
36 region downstream of the *LPL* gene remained significantly associated with high LDL-C levels
37 on multiple regression analysis and variable selection after adjustment for hypertension. The G
38 allele was observed as the risk allele in a recessive model. The variant rs9644568-G in the *LPL*
39 gene was associated with high blood LDL-C levels among Filipinos. In combination with
40 hypertension, this genetic profile may identify individuals who are susceptible to develop high
41 LDL-C in this population.

42

43 * Corresponding author

44 E-mail: eccutiongcodelapaz@up.edu.ph

45 Introduction

46
47 Low-density lipoprotein cholesterol (LDL-C) level is a risk factor and a traditional target for
48 preventive cardiovascular disease (CVD) interventions. This association is enhanced in the presence
49 of atherosclerosis [1], and the common view is that it is an active component of atherogenesis [2].
50 Several studies have since reported reduced adverse cardiovascular events after treatment with LDL-
51 C-lowering drugs [2-4].

52 LDL-C levels may be affected by several factors, including genetics. A common familial form
53 of LDL-C elevation, familial hypercholesterolemia (FH), has been well studied and three causative
54 genes have already been identified, namely *low-density lipoprotein receptor (LDLR)*, *apolipoprotein*
55 *B (APOB)*, and *proprotein convertase subtilisin/kexin type 9 (PCSK9)*. In addition, several studies on
56 hereditary dyslipidemias have shown a variety of genes involved, such as *low density lipoprotein*
57 *receptor adaptor protein 1 (LDLRAP1)*, *ATP binding cassette subfamily G members 5 and 8*
58 *(ABCG5, ABCG8)*, *angiopoietin like 3 (ANGPTL3)*, *microsomal triglyceride transfer protein*
59 *(MTTP)*, *myosin regulatory light chain interacting protein (MYLIP)*, *apolipoproteins A5, B, C2 and*
60 *E (APOA5, APOB, APOC2, APOE)*, and *lipoprotein lipase (LPL)*, which as expected, are involved in
61 lipid metabolism, transport and processing [5,6].

62 Genotyping efforts in recent years attempted to find possible genetic susceptibility loci. For
63 instance, genome-wide association studies (GWAS) have implicated *LDLR*, *APOE*, and *3-hydroxy-3-*
64 *methylglutaryl-coenzyme A reductase (HMGCR)* as possible key regulators of lipid metabolism to
65 high LDL-C [7-9]. Other genes that were considered include *fatty acid desaturase 1 (FADS1)*,
66 *polypeptide N- acetylgalactosaminyltransferase 2 (GALNT2)*, and *acetyl-coenzyme A carboxylase*
67 *beta (ACACB)* [10-12].

68 However, findings from studies of genetic polymorphisms cannot be generalized across
69 populations due to inherent inter-ethnic differences in genetic profiles. To illustrate, among the
70 Taiwanese population, a *PCSK9* variant has been determined to have a causally significant
71 association with high LDL-C levels; however, this association is not found among the Italian
72 population [13,14]. In another study, a novel polymorphism of the *ICAMI* was reported to be

73 associated with LDL-C in African Americans at conventional genome-wide significance, but not
74 among Hispanics and East Asians [15]. Such discrepancies warrant verifying associations between
75 genotypes and LDL-C levels in newly investigated populations. This could be due to independently
76 evolved genetic differences with similar phenotypes due to metabolic proximity. Data from different
77 ethnic populations will be able to contribute to a better understanding of diseases and can enhance
78 customized clinical applications for individual populations.

79 Due to scarce data on genetic associations with LDL-C among Filipinos, this study aimed to
80 identify candidate genetic markers associated with high LDL-C levels in this population. In addition
81 to direct association, the variants were interpreted in the context of traditional risk factors to account
82 for their significant, but potentially interdependent influences.

83 **Methodology**

84

85 **Study design and ethics clearance**

86

87 This is an age- and sex-matched case-control study performed from July 9, 2013 to March
88 31, 2017. This study complied to the Principles of the Declaration of Helsinki (2013) and all
89 experimental protocols in this study were approved by the University of the Philippines Manila-
90 Research Ethics Board (Study protocol code UPMREB- 2012-0186-NIH). The investigators confirm
91 that the methods complied with the relevant guidelines and regulations of UPMREB.

92 **Enrollment of participants and clinical data collection**

93

94 Participants were enrolled from the Philippine General Hospital, different local communities,
95 and clinics in Metro Manila. They were unrelated, aged 18 years old and above, of Filipino descent
96 up to the 3rd degree of consanguinity, and could provide independent consent. Cases were defined as
97 (a) having at least one reading of serum LDL-C ≥ 160 mg/dl as defined by the NCEP ATP III
98 guidelines; and (b) had not ever been on antilipidemics. Controls were participants with (a) at least
99 one reading of serum LDL-C < 160 mg/dl; and (b) without a previous diagnosis of dyslipidemia.
100 Participants were excluded if they had end-stage renal disease, decompensated chronic liver disease,
101 active malignancy, chronic lung disease, secondary hypertension, secondary dyslipidemia, or if
102 pregnant. The demographic data and clinical characteristics were obtained from patient records and

103 verbal interviews. Clinical data, including lipid profile and serum creatinine, were also recorded.

104 Written informed consent forms duly approved by the UPMREB was obtained from potential

105 participants prior to recruitment to the study.

106 **DNA extraction and quantification**

107

108 DNA was extracted using the QiaAmp DNA Mini Kit following the spin protocol for blood

109 buffy coat as specified in the manufacturer's instruction manual. DNA was quantified using a

110 spectrometer at 260nm and stored at -20°C until use. All DNA samples had A-260nm/A-280nm values

111 above 1.80.

112 **Customized genotyping**

113

114 A customized GoldenGate Genotyping (GGGT) beadchip (Illumina, Inc., San Diego, CA,

115 USA) was designed in 2012 using candidate SNPs from both coding and noncoding regions,

116 including intergenic and intronic SNPs, which have shown evidence of association with high LDL-

117 C levels and lipid metabolism. These were selected after an extensive search in the following databases:

118 Pharmacogenomics Knowledgebase database (PharmGKB), National Human Genome Research

119 Institute Genome-Wide Association Study Catalog (NHGRI GWAS Catalog), PubMed, and selected

120 international patent databases (e.g., Patentscope and Espacenet). The selected SNPs were submitted

121 to Illumina, Inc. for scoring to determine the suitability of the SNPs to discriminate for microarray

122 assay and to estimate their specificity.

123 Customized genotyping of candidate SNPs was performed using DNA microarray

124 technology following the GoldenGate Genotyping (GGGT) protocol specified in the manufacturer's

125 manual. While the microarray platform is optimally designed to detect bi-allelic SNPs, the study

126 included tri- or quad-allelic SNPs using the reference allele and the most common alternative in cases

127 where the variants correlate with significant clinical outcomes. After microarray processing, the

128 beadchip was imaged on the HiScan System, and data from these images were analyzed using

129 GenomeStudio software.

130

131

132 **Data analysis**

133 **Quality control**

134
135
136 GenomeStudio 2.0 and PLINK version 2.05.10 were used for data cleanup using the
137 following criteria: call rates $\geq 95\%$, minor allele frequency (MAF) of ≥ 0.01 , genotype
138 missingness of ≤ 0.05 , individual missingness ≤ 0.05 , and not having a Hardy-Weinberg
139 equilibrium (HWE) of $p < 0.001$ in the control group.
140
141

142 **Statistical analysis**

143
144 Chi-squared test and Fisher exact test, as applicable, were used for categorical data, and the
145 student *t*-test was used for quantitative data were performed to assess for significant differences
146 between alleles and genotypes (i.e., allelic and genotypic association tests, which include additive,
147 dominant and recessive models). These models were identified based on the distribution of the case
148 and control genotypes. Tests for allelic and genotypic associations were done by setting the cut-off
149 at Bonferroni-corrected $p < 0.05$.


150 Upon determination of genotypic effects, the genotypes were recorded according to the most
151 significant model, with imputations made for missing data. Univariate analysis was done to determine
152 the association of SNPs with high LDL-C phenotype. A multiple logistic regression using stepwise
153 backward elimination was performed with nominal $p \leq 0.05$ and clinical variable with $p \leq 0.20$.

154 **Results**

155
156 After data quality control, the final set of samples for analysis included 120 participants
157 consisting of 60 cases and 60 controls (Fig 1A). Using age- and sex-matched case-control design,
158 the 120 participants were genotyped using 132 genomic variants.

159 Of the 132 variants selected for the study, 50 variants were removed after quality control
160 with PLINK: 33 SNPs failed the Hardy-Weinberg test ($p > 0.001$) among controls, ten SNPs had
161 missing genotype data for more than 5% of the individuals, and one SNP was removed because the
162 minor allele frequency was lower than 1% (Fig 1B). Eleven variants were significantly associated
163 with high LDL-C after adjusting for multiple testing (i.e., Bonferroni-adjusted $\alpha = 0.05$).
164

165
166



167 **FIG 1. Schematic diagram of data processing and analysis for the high LDL-C group.** A total
168 of 183 participants (A) and 132 SNPs (B) were analyzed to determine the association of genetic
169 variants with high LDL-C and lipid metabolism. Abbreviations: MIND – individual missingness;
170 SNP – single nucleotide polymorphism; HWE – Hardy-Weinberg equilibrium; GENO – genotypic
171 missingness
172

173 Table 1 summarizes the clinical characteristics of the included participants. Their crude
174 odds ratios are in Table S1. Participants in the high LDL-C group tend to have more comorbidities
175 that showed significance such as hypertension ($p < 0.0001$), BMI ≥ 25 kg/m² ($p = 0.056$), and
176 ischemic heart disease ($p = 0.002$). The cases also seemed to have slightly elevated creatinine levels.
177

TABLE 1. Clinical characteristics of participants included in the study

Characteristics	Participants with high LDL-C (n = 60)	Participants with normal LDL-C (n = 60)	p-value*
Age ≥ 60 years, %	40.00	40.00	1.000
Sex, % male	38.33	38.33	1.000
Co-morbidities, %			
Hypertension	86.67	28.33	< 0.001
BMI ≥ 25 kg/m ²	43.33	26.67	0.056
Diabetes mellitus	20.00	0.00	> 0.999
Previous stroke	1.67	1.67	1.000
Ischemic heart disease	45.00	13.33	0.002
eGFR < 60 ml/min	10.00	5.00	0.215
Lifestyle factors, %			
Smoker (both current and past)	28.33	25.00	0.638
Alcohol drinker (>2 shots per day)	50.00	46.67	0.618
Blood chemistry			
Creatinine, mg/dl	0.90 (0.42)	0.80 (0.19)	0.094
Total cholesterol, mg/dl	273.79 (44.54)	193.01 (25.66)	< 0.001
Triglycerides, mg/dl	159.47 (68.76)	91.70 (36.67)	< 0.001
HDL, mg/dl	52.46 (14.19)	56.94 (13.50)	0.079
LDL, mg/dl	191.88 (41.34)	120.62 (21.87)	< 0.001
eGFR, ml/min	87.72 (24.42)	93.33 (18.77)	0.161

Abbreviations: SD – standard deviation; BMI – body mass index; eGFR – estimated glomerular filtration rate; HDL – high-density lipoprotein; LDL – low-density lipoprotein
 *Significance set at $p < 0.05$ using Chi-squared test for age and sex, conditional logistic regression for comorbidities and lifestyle factors, and Student's *t* test for continuous variables

178

179

There were 11 variants found to have a statistically significant association with LDL-C levels on the genotypic association test after adjusting for multiple testing (Bonferroni-adjusted $\alpha = 0.00061$) (Table S2). These variants underwent logistic regression analysis for the computation of their OR and to determine which will retain significance upon adjusting for other variables (Table 2). One SNP had clinically significant odds ratios ($OR \geq 2.5$) and was statistically significant ($p < .001$) on simple logistic regression analysis: rs12279250 in NELL1. This SNP seemed to display a dominant genotypic effect.

186

187

188

Clinical variables with a significant difference between the two groups, $p \leq 0.20$: hypertension, $BMI \geq 25 \text{ kg/m}^2$, and ischemic heart disease were included together with the 11 variants with nominal $p < 0.05$ in the full model for the multiple regression analysis (Table 3). On variable selection using the stepwise algorithm ($p < 0.05$), only the presence of hypertension and rs9644568 retained their significant association with high LDL-C levels under an additive model with allele G as the risk allele (AG vs. GG: adjusted OR = 2.44, 95% CI = 0.41-20.60; $p = 0.355$;

194

TABLE 2. Univariate logistic regression analysis of the significant variants

SNP	Chr	Implicated Gene	Variant Role	Risk Allele	Risk Allele Frequency	Genotype	Crude Odds Ratio (95% CI)	<i>p</i> -value*
rs9644568	8	LPL	Intergenic (regulates LPL as by GTex Portal)	G	0.60	AG vs AA	2.36 (0.50, 17.27)	0.320
						GG vs AA	13.00 (3.27, 87.36)	0.001
rs1045642	7	ABCB1	synonymous variant	A	0.325	AG vs AA	2.43 (1.03, 5.94)	0.046
						GG vs AA	7.33 (2.58, 23.07)	<0.001
rs12279250	11	NELL1	intron variant	G	0.54	GG vs AG/AA	2.20 (1.01, 4.96)	0.051
rs1532085	15	LIPC	unknown	A	0.20	AG vs GG	2.44 (1.05, 5.80)	0.039
						AA vs GG	5.33 (1.88, 18.47)	0.003

195

GG vs AA: adjusted OR = 10.66, 95% CI = 2.15-81.05; $p = 0.008$) (Table 4).

rs4149268	9	ABCA1	intron variant	G	0.26	AG vs AA	2.86 (1.25, 6.73)	0.014
						GG vs AA	4.72 (1.71, 14.22)	0.004
rs4299376	2	ABCG8	intron / upstream gene variant	C	0.70	AC vs CC	0.75 (0.17, 3.56)	0.706
						CC vs AA	3.41 (1.02, 13.43)	0.056
rs676210	2	APOB	missense variant	A	0.38	AG vs GG	2.95 (1.21, 7.47)	0.019
						AA vs GG	4.31 (1.69, 11.56)	0.003
rs776746	7	CYP3A5	splice acceptor / intron / 5'- UTR variant	G	0.37	AG vs AA	3.10 (1.26, 8.15)	0.017
						GG vs AA	6.79 (2.38, 21.20)	0.001
rs2686586	3	GOLIM4	upstream gene variant; intergenic	A	0.35	AG vs GG	4.35 (1.74, 11.66)	0.002
						AA vs GG	7.03 (2.59, 20.73)	<0.001
rs7016880	8	LPL	downstream gene variant	G	0.56	GC vs GG	0.71 (0.20, 2.38)	0.578
						CC vs GG	3.60 (1.44, 9.54)	0.007
rs660240	1	CELSR2	3'-UTR variant	G	0.68	AG vs AA	2.78 (0.58, 20.45)	0.240
						GG vs AA	7.58 (1.84, 51.54)	0.012

ABCB1 = ATP binding cassette subfamily B member 1; ABCA1 = ATP binding cassette subfamily A member 1; ABCG8 = ATP binding cassette subfamily G member 8; APOB = apolipoprotein B; CELSR2 = cadherin EGF LAG seven-pass G-type receptor 2; CI = confidence interval; CYP3A5 = cytochrome P450 family 3 subfamily A member 5; GOLIM4 = golgi integral membrane protein 4; INTS10 = integrator complex subunit 10; LIPC = lipase C; LPL = lipoprotein lipase; NELL1 = neural EGFL like 1; SLC18A1 = solute carrier family 18 member A1; SNP = single nucleotide polymorphism; ZPR1 = zinc finger protein ZPR1;

*Significance set at $p < 0.05$ on conditional logistic regression analysis

196

TABLE 3. Genetic variants and clinical factors in the multiple regression full model.

Factors	Genotype	Adjusted OR (95% CI)	p-value
Hypertension	-	28.02 (6.14, 183.90)	< 0.001
BMI ≥ 25 kg/m ²	-	3.73 (0.95, 16.69)	0.068
Ischemic heart disease	-	0.37 (0.06, 1.95)	0.259
rs9644568	AG vs AA	1.92 (0.17, 33.73)	0.612
	GG vs AA	38.82 (2.08, 1758.82)	0.030
rs1045642	AG vs AA	4.96 (0.75, 40.90)	0.111
	GG vs AA	18.82 (1.53, 358.85)	0.032
rs12279250	AA vs AG/GG	2.37 (0.35, 15.77)	0.359
rs1532085	AG vs GG	0.66 (0.07, 5.18)	0.697
	AA vs GG	3.90 (0.46, 40.06)	0.221
rs4149268	AG vs AA	4.89 (1.00, 27.94)	0.058
	GG vs AA	22.36 (2.73, 270.92)	0.007
rs4299376	AG vs GG	0.25 (0.01, 3.89)	0.333

	AA vs GG	0.08 (<0.01, 1.40)	0.101
rs676210	AG vs GG	1.22 (0.17, 8.13)	0.838
	AA vs GG	0.82 (0.10, 6.54)	0.848
rs776746	AG vs AA	2.64 (0.41, 18.38)	0.309
	GG vs AA	11.57 (1.18, 163.68)	0.047
rs2686586	AG vs AA	0.27 (0.03, 2.38)	0.240
	GG vs AA	0.81 (0.08, 8.64)	0.860
rs7016880	GC vs GG	0.17 (0.01, 2.48)	0.212
	CC vs GG	0.11 (0.01, 1.22)	0.088
rs660240	AG vs AA	44.94 (1.47, 6062.32)	0.068
	GG vs AA	8.43 (0.44, 241.37)	0.174

BMI = body mass index; CI = confidence interval; OR = odds ratio

197

198

TABLE 4. Genetic variants and clinical factors remaining after variable selection.

Variable	Genotype	Adjusted OR (95% CI)	p-value
rs9644568	AG vs AA	2.44 (0.41, 20.60)	0.355
	GG vs AA	10.66 (2.15, 81.05)	0.008
Hypertension	-	14.23 (5.53, 40.81)	< 0.001

199

*Significance set at $p < 0.05$; Abbr: CI = confidence interval; OR = odds ratio

200

Discussion

201

202

203

Genetic determinants of high LDL-C may be helpful in the understanding and optimum management of cardiovascular risk. As associated variations often differ across populations, especially for complex conditions, studies on Filipinos must be undertaken considering that cardiovascular disease remains as the top cause of mortality in the country. This study analyzes candidate genetic variants of high LDL-C among Filipino patients. In addition, a regression model of candidate genetic variants incorporating traditional clinical risk factors was generated to assess their relative effects on LDL-C profiles.

209

210

Univariate analyses found 11 variants associated with LDL-C levels. The reported genes include *lipoprotein lipase (LPL)*, *ATP binding cassette subfamily B member (ABCB1)*, *lipase C (LIPC)*, *ATP binding cassette subfamily A member (ABCA1)*, *ATP binding cassette subfamily G member 8 (ABCG8)*, *apolipoprotein B (APOB)*, and *cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2)*. Expectedly, these are known genes whose roles in LDL-C metabolism are well established — from lipid transport, cellular metabolism and homeostasis, cellular translocation, and storage [16-21].

216

217 A major finding in this study is the variant rs9644568 near the *LPL* gene. Logistic
218 regression with adjustment for hypertension shows a significant association of rs9644568 to high
219 LDL-C levels after adjusting for hypertension among Filipinos. The G allele of rs9644568 confers
220 a 2.44-fold increased risk for high LDL-C in heterozygous individuals and a 10.66-fold increased
221 risk in homozygous individuals. This suggests a possible additive or a multiplicative model of
222 transmission. This is similar to the findings of a genome-wide association study among Europeans,
223 which consistently demonstrated the significant association of G allele of rs4977574 with high LDL-
224 C levels and an increased risk of myocardial infarction (MI) [22]. In contrast, the minor G allele
225 protects LDL-C in another study that included Hispanics, East Asians and also Europeans [23]. A
226 similar study found the minor G allele to be associated with decreased risk for coronary artery
227 disease and peripheral artery disease in a Chinese population with diabetes [24].

228 The SNP rs9644568 is located on chromosome 8p21.3 in an intergenic region downstream
229 of the gene *LPL* (UCSC Genome Browser, <http://genome.ucsc.edu>. Accessed October 10,
230 2023). Although the variant is >100 kb far from the gene *LPL*, expression from several tissues
231 suggests that it regulates the gene (GTEx Portal, <https://gtexportal.org>. Accessed October 10, 2023).
232 This gene is predominantly expressed in the heart, skeletal muscles, and adipose tissues²⁵. *LPL*
233 encodes a rate-limiting enzyme called lipoprotein lipase, which plays an important role in lipid
234 metabolism, as well as in lipid intake and clearance. Lipoprotein lipase aids in the breakdown of
235 the circulating triglyceride-rich lipoproteins in the bloodstream and the uptake of free fatty acids
236 into peripheral organs for energy storage and consumption [26-30]. Alterations in *LPL* activity
237 could result in dyslipidemia, characterized by increased plasma LDL-C, TG, and reduced plasma
238 HDL-C levels [31]. This association of the variant is interesting, as prior data, to our knowledge, do
239 not indicate rs9644568 as a risk marker for high LDL levels or as having the highest odds ratio in
240 any non-Filipino population. This can imply that the variant is a unique risk marker for Filipinos,
241 independent of other components of metabolic syndrome, i.e., hypertension and diabetes mellitus.

242 To support the significance of *LPL* as a candidate locus, the study also indicated that another
243 downstream *LPL* variant, rs7016880, was associated with LDL-C. Interestingly, rs7016880 shares

244 many characteristics with rs9644568 – being located as a downstream non-coding regulator,
245 having a possible multiplicative model, with a high odds ratio. This may provide greater confidence
246 for the veracity of the findings in this study.

247 As for the other variants, the adjustments due to hypertension and the rs9644568 seem to
248 mask their statistical significance. This has several implications. First, rs9644568 is rarely reported
249 as a marker for LDL-C in the literature, but the statistical significance of rs9644568 stood out
250 prominently in the current study, thus implying that the SNP is unique among the Filipino
251 population. Second, hypertension might have masked the statistical significance of some of the
252 candidate genes in the metabolic syndrome context. This is unsurprising as some variants have been
253 previously associated with high blood pressure. To illustrate, *ABCB1* was reported to be associated
254 with hypertension through dietary salt transport and retention [32]. In a study among Han Chinese,
255 variants of *ABCA1*, rs2472510 and rs2515614, were associated with hypertension, with decreased
256 expression of *ABCA1* linked with hypertension risk [33]. On the other hand, meta-analysis of 2799
257 cases and 6794 controls showed an association of *CYP3A5* rs776746 with hypertension [34]. A later
258 study on a small sample of Han Chinese also reported a significant association of *CYP3A5* rs776746
259 with the elevated risk of hypertension [35].

260 Several variants are mostly known genes whose roles in LDL-C metabolism are well
261 established [16-21]. The G allele of rs1532085 in *LIPC* with a protective effect for LDL-C levels
262 in Chinese populations [36], is similar to the findings in this study. In a large GWAS study involving
263 >100,000 Caucasians, rs4299376 in *ABCG8* was found to be one of the strongly associated genes
264 with LDL-C [38]. The variant rs676210 in *APOB* has been identified as a susceptibility locus for
265 very low-density lipoprotein levels in the Women's Genome Health Study (WGHS) involving
266 17,296 women of European ancestry [38]. This association was further reported in the Chinese
267 Yugur population³⁹. A GWAS study of 11,685 showed a significant association of *CELSR2* rs660240
268 to LDL-C levels where the G allele is associated with risk and this was confirmed in a meta-analysis
269 of Below et al. (2016) [40,41].

270 However, some genes can be considered as attractive at best at this point. One intriguing

271 finding is the direct association of ABCB1 with LDL-C. There is scarce data on this association, as
272 most studies focused on its association with response to statins [42,43]. The variant ABCB1
273 rs1045642 is by itself associated with statin response [44]. The variant rs12279250 in NELL1, a
274 growth factor of still uncertain significance, has been associated with increased triglyceride levels
275 [45,46], which may lead to a subsequent increase in LDL-C levels. Despite the study identifying
276 rs4149268 in ABCA1 as associated with LDL-C, most studies reported an association with HDL-
277 C levels instead of LDL-C [47]. This may need to be verified, but it is noteworthy to investigate if
278 such an association remains among Filipinos. As for rs776746 in CYP3A5, there is little study on
279 the direct association with LDL-C levels. This could be due to the assumption that cytochrome P
280 proteins are mainly associated with drugs. In fact, most studies focused on response to cholesterol-
281 lowering drugs [48,49]. As the present study focused on participants without drug intake, a possible
282 role for CYP3A5 on LDL-C level could be plausible. Similarly, there is minimal information on
283 rs2686586. Even its association with the gene GOLIM4 is questionable, as no evidence of
284 regulation nor proximity (>50kb) is noted in the literature. Nonetheless, the fact that it is
285 significantly associated with LDL-C needs to be verified.

286 In this study, clinical variables that show a significant association with high LDL-C
287 phenotype are hypertension, BMI ≥ 25 kg/m², and ischemic heart disease (IHD). Several studies
288 consistently show strong correlations between these comorbidities and LDL-C levels. The link
289 between LDL-C and hypertension was elucidated by the group of Laaksonen et al. (2008). They
290 reported that elevated serum levels of LDL-C increase the risk of hypertension in Finnish men,
291 which explained the strong association of dyslipidemia with incident hypertension [50]. Meanwhile,
292 a previous study performed in the US population suggested a linear association of LDL-C
293 concentrations and BMI [51]. The association between high LDL-C levels and high IHD risk is
294 further substantiated by the study of Breuer (2005), focusing on improving cardiovascular disease
295 outcomes by lowering LDL-C levels [52]. Moreover, dyslipidemia and hypertension are known as
296 major risk factors for cardiovascular diseases; with these two comorbidities reported to be
297 frequently diagnosed in patients with ischemic heart disease [53].

298 This study presents an opportunity to identify individuals at risk for developing high LDL-C
299 levels by looking at their genetic profiles to complement clinical correlates. Estimated associations
300 between variant rs9644568 and hypertension were very high, but the confidence intervals around
301 them were too wide to rule out the possibility of substantial associations. Further studies with larger
302 sample sizes are required to validate the conclusions of this study.

303 **Conclusion**

304 Genetic determinants largely influence the development of high LDL-C levels. This study
305 found an association of variant rs9644568 in the intergenic region downstream of the *LPL* gene,
306 with high LDL-C levels among Filipinos. Adding a genetic component may improve screening and
307 assessment of patients at risk for developing high LDL-C levels.
308

References

309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336

- [1] Mortensen MB, Dzaye, O., Bøtker, H.E., et al. Low-Density Lipoprotein Cholesterol Is Predominantly Associated With Atherosclerotic Cardiovascular Disease Events in Patients With Evidence of Coronary Atherosclerosis: The Western Denmark Heart Registry. *Circulation*. 2023; 147(14): 1053-1063.
- [2] Stanciulescu LA, Scafa-Udriste A & Dorobantu M. Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes-A Comprehensive Review. *Int J Mol Sci*. 2023; 24(7): 6669.
- [3] Abdullah SM, Defina LF, Leonard D, et al. Long-Term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease: results from the Cooper Center Longitudinal Study. *Circulation*. 2018; 138(21): 2315-25.
- [4] Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. *Journal of the American College of Nutrition*. 2008; 27: 1–5.
- [5] Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. *J Clin Lipidol*. 2020; 14(4): 398-413.
- [6] García-Giustiniani D, Stein R. Genetics of Dyslipidemia. *Arq Bras Cardiol*. 2016; 106(5): 434-438.
- [7] Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. *Cancer Prev Res (Phila)*. 2010; 3(5): 597-603.
- [8] Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet*. 2009; 41(1): 47-55.
- [9] Chasman DI, Posada D, Subrahmanyam L, Cook NR, Stanton VP Jr, Ridket PM. Pharmacogenetic study of statin therapy and cholesterol reduction. *JAMA*. 2004; 291(23): 2821-27.
- [10] Rúaño G, Thompson PD, Kane, J.P., et al. Physiogenomic analysis of statin-treated

- 337 patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein
338 cholesterol? *Pharmacog*. 2010; 11(7): 959-7.
- 339 [11] Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid
340 levels and risk of coronary artery disease. *Arterioscler Thromb Vasc Biol*. 2010; 30(11),
341 2264-76.
- 342 [12] Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid
343 concentrations and risk of coronary artery disease. *Nat Genet*. 2008; 40(2): 161-9.
- 344 [13] Hsu LA, Teng MS, Wu S, et al. Common and Rare PCSK9 Variants Associated with Low-
345 Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian
346 Randomization Study. *International Journal of Molecular Sciences*. 2022; 23(18): 10418.
- 347 [14] Guella I, Asselta R, Ardissino D, et al. Effects of PCSK9 genetic variants on plasma LDL
348 cholesterol levels and risk of premature myocardial infarction in the Italian population. *J*.
349 *Lipid Res*. 2010; 51: 342–3349.
- 350 [15] Elbers CC, Guo Y, Tragante V, et al. Gene-Centric Meta-Analysis of Lipid Traits in
351 African, East Asian and Hispanic Populations. *PLoS ONE*. 2012; 7(12): e50198.
- 352 [16] Wu J, Wang X, Chen H, et al. Type 2 Diabetes Risk and Lipid Metabolism Related to the
353 Pleiotropic Effects of an ABCB1 Variant: A Chinese Family-Based Cohort Study.
354 *Metabolites*. 2022; 12: 875.
- 355 [17] Dijk W, Di Filippo M, Kooijman S, et al. Identification of a Gain-of-Function LIPC Variant
356 as a Novel Cause of Familial Combined Hypocholesterolemia. *Circulation*. 2022; 146(10):
357 724-739.
- 358 [18] Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, et al. The Role of the ATP-
359 Binding Cassette A1 (ABCA1) in Human Disease. *Int J Mol Sci*. 2021; 22(4): 1593.
- 360 [19] Benn M, Nordestgaard BG, Jensen JS, et al. Polymorphism in APOB Associated with
361 Increased Low-Density Lipoprotein Levels in Both Genders in the General Population. *The*
362 *Journal of Clinical Endocrinology & Metabolism*. 2005; 90(10): 5797–5803.
- 363 [20] Tada H, Okada H, Nomura A, et al. Beneficial effect of ezetimibe-atorvastatin combination
364 therapy in patients with a mutation in ABCG5 or ABCG8 gene. *Lipids Health Dis*. 2020;

- 365 19(1): 3.
- 366 [21] Tan J, Che Y, Liu Y, et al. CELSR2 deficiency suppresses lipid accumulation in hepatocyte
367 by impairing the UPR and elevating ROS level. *FASEB J.* 2021; 35: e21908.
- 368 [22] Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to
369 polygenic dyslipidemia. *Nat Genet.* 2009; 41(1):56-65.
- 370 [23] Hoffmann TJ, Theusch E, Haldar T, Ranatunga DK, Jorgenson E, Medina MW, et al. A
371 large electronic-health-record-based genomewide study of serum lipids. *Nat Genet.* 2018;
372 50(3): 401.
- 373 [24] Qin J, Tian J, Liu G, et al. Association between 1p13 polymorphisms and peripheral arterial
374 disease in a Chinese population with diabetes. *J Diabetes Investig.* 2018; 9(5):1189-95.
- 375 [25] Kersten S. Physiological regulation of lipoprotein lipase. *202 Biochim Biophys Acta.*
376 1841(7), 919-33 (2014).
377
378
- 379 [26] Merkel M, Kako Y, Radner H, et al. Catalytically inactive lipoprotein lipase expression in
380 muscle of transgenic mice increase very low density lipoprotein uptake: direct evidence that
381 lipoprotein lipase bridging occurs in vivo. *Proc Natl Acad Sci USA.* 1998; 95: 13841–13846.
- 382 [27] Merkel M, Heeren J, Dudeck W, et al. Inactive lipoprotein lipase (LPL) alone increases
383 selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also
384 increases triglyceride hydrolysis and whole particle lipoprotein uptake. *J Biol Chem.* 2002;
385 277: 7405–7411.
- 386 [28] Mead JR, Ramji DP. The pivotal role of lipoprotein lipase in atherosclerosis. *Cardiovasc Res.* 2022;
387 55: 261–269.
388
- 389 [29] Mamputu JC, Desfaits AC, Renier G. Lipoprotein lipase enhances human monocyte
390 adhesion to aortic endothelial cells. *J Lipid Res.* 1997; 38: 1722–1729.
- 391 [30] Pirahanchi Y, Anoruo M, Sharma S. *Biochemistry, Lipoprotein Lipase.* StatPearls.
392 Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.
393 2022.
- 394 [31] Su X, Peng DQ. New insights into ANGPT3 in controlling lipoprotein metabolism and
395 risk of cardiovascular diseases. *Lipids Health Dis.* 2018; 17(1): 12.

- 396 [32] Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension.
397
398 Pharmacogenomics. 2009; 10(3): 477-87 (2009).
399
- 400 [33] Ren Y, Tong E, Di C, et al. Association Between ABCA1 Gene Polymorphisms and the
401 Risk of Hypertension in the Chinese Han Population. *Front Public Health*. 2022; 10: 878610.
- 402 [34] Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism (6986G>A) with
403 blood pressure and hypertension. *Hypertens Res*. 2011; 34(11): 1216-20.
- 404 [35] Li Z, Chen P, Zhou T, et al. Association between CYP3A5 genotypes with hypertension
405 in Chinese Han population: A case-control study. *Clin Exp Hypertens*. 2017; 39(3): 235-240.
- 406 [36] Khounphinith E, Yin RX, Qiu L, et al. Association of the LIPC rs1532085 SNP and serum
407 lipid traits in the Chinese Maonan and Han populations. *Int J Clin Exp Pathol*. 2018; 11(4),
408 :2038-2052.
- 409 [37] Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance
410 of 95 loci for blood lipids. *Nature*. 2010; 466(7307): 707-13.
- 411 [38] Chasman DI, Paré G, Mora S, et al. Forty-three loci associated with plasma lipoprotein
412 size, concentration, and cholesterol content in genome-wide analysis. *PLoS Genet*. 2009;
413 5(11): e1000730.
- 414 [39] Gu QL, Han Y, Lan YM, et al. Association between polymorphisms in the APOB gene
415 and hyperlipidemia in the Chinese Yugur population. *Braz J Med Biol Res*. 2017; 50(11):
416 e6613.
- 417 [40] Sandhu MS, Waterworth DM, Debenham SL, et al. LDL-cholesterol concentrations: a
418 genome-wide association study. *Lancet*. 2008; 371(9611): 483-91.
- 419 [41] Below JE, Parra EJ, Gamazon ER, et al. Meta-analysis of lipid-traits in Hispanics identifies
420 novel loci, population-specific effects, and tissue-specific enrichment of eQTLs. *Sci Rep*. 6,
421 19429 (2016).
- 422 [42] Kadam P, Ashavaid TF, Ponde CK, et al. Genetic determinants of lipid-lowering response
423 to atorvastatin therapy in an Indian population. *J Clin Pharm Ther*. 2016; 41(3): 329-33.
- 424 [43] Shatnawi A, Kamran Z, Al-Share Q. Pharmacogenomics of lipid-lowering agents: the
425 impact on efficacy and safety. *Per Med*. 2023; 20(1): 65-86.

- 426 [44] Sun L, Wolska A, Amar M, et al. Approach to the Patient With a Suboptimal Statin
427 Response: Causes and Algorithm for Clinical Management. *J Clin Endocrinol Metab.* 2023;
428 108(9): 2424-2434.
- 429 [45] Cheng X, Shi J, Jia Z, et al. NELL-1 in Genome-Wide Association Studies across Human
430 Diseases. *Am J Pathol.* 2022; 192(3): 395-405.
- 431 [46] Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome-wide association
432 analyses suggest NELL1 influences adverse metabolic response to HCTZ in African
433 Americans. *Pharmacogenomics J.* 2014; 14(1): 35-40.
- 434 [47] Paththinige CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited
435 susceptibility to hypercholesterolemia - a comprehensive literature review. *Lipids Health Dis.*
436 2017; 16(1): 103.
- 437 [48] Jiang XY, Zhang Q, Chen P, et al. CYP7A1 polymorphism influences the LDL cholesterol-
438 lowering response to atorvastatin. *J Clin Pharm Ther.* 2012; 37(6): 719-23.
- 439 [49] Lim MYC, Tee JR, Yau WP, et al. A meta-analysis of the pooled impact of CYP7A1 single
440 nucleotide polymorphisms on serum lipid responses to statins. *Front Genet.* 2023; 14:
441 1199549.
- 442 [50] Laaksonen DE, Niskanen L, Nyysönen K, et al. Dyslipidaemia as a predictor of
443 hypertension in middle-aged men. *Eur Heart J.* 2008; 29(20): 2561-8.
- 444 [51] McLaughlin T, Allison G, Abbasi F, et al. Prevalence of insulin resistance and associated
445 cardiovascular disease risk factors among normal weight, overweight, and obese individuals.
446 *Metabolism.* 2004; 53(4): 495-9.
- 447 [52] Breuer HW. Low Density Lipoprotein Cholesterol and Coronary Heart Disease - Lower is
448 Better. *European Cardiology.* 2005; 1(1): 1-6.
- 449 [53] Singh BM, Mehta JL. Interactions Between the Renin-Angiotensin System and
450 Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease. *Arch*
451 *Intern Med.* 2003; 163(11): 1296–1304.
- 452
- 453

454 **Acknowledgements**

455

456 The authors would like to express their sincere gratitude to the administrative staff and
457 researchers of the Microarray Laboratory of the Institute of Human Genetics, National Institutes
458 of Health-University of the Philippines Manila, the Philippine Genome Center, and the clinical
459 fellows of the Department of Medicine for actively being involved in the project. We are
460 extending our gratitude to our sponsor, the Philippine Council for Health Research and
461 Development of the Department of Science and Technology (PCHR-DOST)

462 **Author Contributions**

463 **EMCutiongco-De La Paz**, conceptualized the study and designed the methodology, acquired
464 funding and led the project administration and supervision, conducted the research and
465 investigation process, performed the data curation and analysis, interpreted the data, wrote the
466 original draft, reviewed and edited the manuscript for intellectual content; **JBNevalo**
467 conceptualized the study and designed the methodology, acquired funding and led the project
468 administration and supervision, conducted the research and investigation process, performed the
469 data curation and analysis, interpreted the data, wrote the original draft, reviewed and edited the
470 manuscript for intellectual content; **LEGSantos**, conceptualized the study and designed the
471 methodology, conducted the research and investigation process, interpreted the data;
472 **AYCLAman**, acquired funding and led the project administration and supervision, conducted the
473 research and investigation process, performed the data curation and analysis, interpreted the data,
474 wrote the original draft; **JDAMagno**, conceptualized the study and designed the methodology,
475 conducted the research and investigation process, interpreted the data; **PMMReganit**,
476 conceptualized the study and designed the methodology, conducted the research and investigation
477 process, interpreted the data; **RHPTiongco**, conceptualized the study and designed the
478 methodology, conducted the research and investigation process, interpreted the data; **DIDOna**,
479 conceptualized the study and designed the methodology, conducted the research and investigation
480 process, interpreted the data; **FERPunzalan**, conceptualized the study and designed the
481 methodology, conducted the research and investigation process, interpreted the data; **EJBLlanes**,

482 conceptualized the study and designed the methodology, conducted the research and investigation
483 process, interpreted the data; **JAMAherrera**, conducted the research and investigation process,
484 interpreted the data; **CMOFernandez**, performed the data curation and analysis, interpreted the
485 data, reviewed and edited the manuscript for intellectual content; **LLAbrahan**, conducted the
486 research and investigation process, interpreted the data; **CFAgustin**, conducted the research and
487 investigation process, interpreted the data; **AJPBejarin**, conducted the research and investigation
488 process, performed the data curation and analysis, interpreted the data, wrote the original draft;
489 **RGSy**, conceptualized the study and designed the methodology, acquired funding and led the
490 project administration and supervision, conducted the research and investigation process,
491 interpreted the data, reviewed and edited the manuscript for intellectual content

492 **Data Availability Statement**

493 The datasets used and/or analyzed during the current study are available from the corresponding
494 author on reasonable request.

495 **Competing Interests**

496 The authors declare no competing interests.

497 **Funding Source**

498
499 The present study was sponsored by a grant-in-aid from the PCHRD-DOST
500